Subject: Market Research Survey on the Selection of Beta-blocker and Beta-Blocker-Based FDCs for Hypertension Management with Various Comorbidities (BETA-HTN INSIGHTS)
The global burden of cardiovascular diseases (CVDs), such as hypertension, is escalating, primarily due to a rapid health transition in developing countries. CVDs are the leading causes of death worldwide. Hypertension (HTN) affects over 1.28 billion adults aged 30-79 years, with 46% unaware of their condition, causing about 12.8% of all deaths annually (7.5 million). It is a major risk factor for cardiovascular diseases like CAD, stroke, heart failure, and chronic kidney disease, imposing significant economic burdens. Common risk factors include high salt intake, unhealthy diet, physical inactivity, obesity, alcohol consumption, tobacco use, and genetics. The prevalence is highest in Africa (46% of adults) and lowest in the Americas (35%), influenced by socioeconomic factors, healthcare access, and lifestyle.
Hypertension has emerged as a major disease burden, contributing to increased mortality. Compared to earlier reports, hypertension prevalence in India has shown an increasing trend during the past two decades, with the most recent national estimates of up to 30%. there is a continuous relationship between blood pressure and cardiovascular or renal morbid or fatal events starting from an office systolic blood pressure >115 mmHg and a diastolic blood pressure >75 mmHg. The complications of high BP can be classified as short- and long-term consequences.
Consistent observational evidence suggests high BP is the leading cause of long-term consequences such as heart failure, with and without preserved ejection fraction, atrial fibrillation, valvular heart disease, peripheral arterial disease and aortic syndromes, chronic kidney disease and end stage renal disease, dementia and Alzheimer’s Disease.
There is limited real-world data on the practice patterns for managing hypertension (HTN) and coronary artery disease (CAD) patients in India, particularly regarding the use of Beta-blocker- based triple-drug fixed-dose combinations (FDCs). Despite their established role in cardiovascular disease management, the selection and utilization of Beta-blockers in combination therapies vary based on patient profiles, comorbid conditions, and clinician preferences. The purpose of this survey is to gain insights into the clinical perceptions and prescribing trends of Beta-blocker-based triple therapy in hypertension and CAD management. It aims to assess the efficacy, safety, and patient outcomes associated with these therapies, identify challenges in real- world practice, and explore unmet needs to optimize treatment strategies for better cardiovascular outcomes.
We invite you to participate in this market research study. On acceptance, you will need to capture the relevant data as mentioned in the standard set of questions provided.
We would encourage you to carefully fill all available information to the fullest as recommended in the set of questionnaires.
If you agree to participate in the said study, we would request you to sign and return the enclosed reply along with your visiting card for accuracy of records.
|
}}){kind=logo}
}})